• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

细胞渗透性肽基抑制剂对μ-钙蛋白酶和20S蛋白酶体蛋白酶活性的特异性

Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome.

作者信息

Mellgren R L

机构信息

Department of Pharmacology and Therapeutics, Medical College of Ohio, Toledo, Ohio 43614-5804, USA.

出版信息

J Biol Chem. 1997 Nov 21;272(47):29899-903. doi: 10.1074/jbc.272.47.29899.

DOI:10.1074/jbc.272.47.29899
PMID:9368065
Abstract

Cell-permeant peptidyl aldehydes and diazomethylketones are frequently utilized as inhibitors of regulatory intracellular proteases. In the present study the specificities of several peptidyl inhibitors for purified human mu-calpain and 20 S proteasome were investigated. Acetyl-LLnL aldehyde, acetyl-LLM aldehyde, carbobenzyloxy-LLnV aldehyde (ZLLnVal), and carbobenzyloxy-LLY-diazomethyl ketone produced half-maximum inhibition of the caseinolytic activity of mu-calpain at concentrations of 1-5 x 10(-7) M. In contrast, only ZLLnVal was a reasonably potent inhibitor of the caseinolytic activity of 20 S proteasome, producing 50% inhibition at 10(-5) M. The other inhibitors were at least 10-fold less potent, producing substantial inhibition only at near saturating concentrations in the assay buffer. Further studies with ZLLnVal demonstrated that its inhibition of the proteasome was independent of casein concentration over a 25-fold range. Proteolysis of calpastatin or lysozyme by the proteasome was half-maximally inhibited by 4 and 22 microM ZLLnVal, respectively. Thus, while other studies have shown that ZLLnVal is a potent inhibitor of the hydrophobic peptidase activity of the proteasome, it appears to be a much weaker inhibitor of its proteinase activity. The ability of the cell permeant peptidyl inhibitors to inhibit growth of the yeast Saccharomyces cerevisiae was studied because this organism expresses proteasome but not calpains. Concentrations of ZLLnVal as high as 200 microM had no detectable effect on growth rates of overnight cultures. However, yeast cell lysates prepared from these cultures contained 2 microM ZLLnVal, an amount which should have been sufficient to fully inhibit hydrophobic peptidase activity of yeast proteasome. Degradation of ubiquitinylated proteins in yeast extracts by endogenous proteasome was likewise sensitive only to high concentrations of ZLLnVal. The higher sensitivity of the proteinase activity of calpains to inhibition by the cell permeant inhibitors suggests that calpain-like activities may be targets of these inhibitors in animal cells.

摘要

细胞渗透性肽基醛和重氮甲基酮常被用作细胞内调节蛋白酶的抑制剂。在本研究中,研究了几种肽基抑制剂对纯化的人μ-钙蛋白酶和20S蛋白酶体的特异性。乙酰-LLnL醛、乙酰-LLM醛、苄氧羰基-LLnV醛(ZLLnVal)和苄氧羰基-LLY-重氮甲基酮在浓度为1-5×10^(-7)M时对μ-钙蛋白酶的酪蛋白水解活性产生半数最大抑制。相比之下,只有ZLLnVal是20S蛋白酶体酪蛋白水解活性的有效抑制剂,在10^(-5)M时产生50%的抑制。其他抑制剂的效力至少低10倍,仅在测定缓冲液中接近饱和浓度时才产生显著抑制。对ZLLnVal的进一步研究表明,其对蛋白酶体的抑制在25倍的范围内与酪蛋白浓度无关。蛋白酶体对钙蛋白酶抑制蛋白或溶菌酶的蛋白水解分别被4和22μM的ZLLnVal半数最大抑制。因此,虽然其他研究表明ZLLnVal是蛋白酶体疏水肽酶活性的有效抑制剂,但它似乎是其蛋白酶活性的弱得多的抑制剂。研究了细胞渗透性肽基抑制剂抑制酿酒酵母生长的能力,因为这种生物体表达蛋白酶体但不表达钙蛋白酶。高达200μM的ZLLnVal浓度对过夜培养物的生长速率没有可检测到的影响。然而,从这些培养物中制备的酵母细胞裂解物含有2μM的ZLLnVal,这一量应该足以完全抑制酵母蛋白酶体的疏水肽酶活性。内源性蛋白酶体对酵母提取物中泛素化蛋白质的降解同样仅对高浓度的ZLLnVal敏感。钙蛋白酶的蛋白酶活性对细胞渗透性抑制剂抑制的更高敏感性表明,类似钙蛋白酶的活性可能是动物细胞中这些抑制剂的作用靶点。

相似文献

1
Specificities of cell permeant peptidyl inhibitors for the proteinase activities of mu-calpain and the 20 S proteasome.细胞渗透性肽基抑制剂对μ-钙蛋白酶和20S蛋白酶体蛋白酶活性的特异性
J Biol Chem. 1997 Nov 21;272(47):29899-903. doi: 10.1074/jbc.272.47.29899.
2
Inhibition of growth of human TE2 and C-33A cells by the cell-permeant calpain inhibitor benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone.
Exp Cell Res. 1994 Nov;215(1):164-71. doi: 10.1006/excr.1994.1328.
3
Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine.双亮氨酸和三亮氨酸的肽基醛对钙蛋白酶和蛋白酶体活性的差异性抑制作用
J Biochem. 1996 Mar;119(3):572-6. doi: 10.1093/oxfordjournals.jbchem.a021280.
4
Comparison of the effect of calpain inhibitors on two extralysosomal proteinases: the multicatalytic proteinase complex and m-calpain.钙蛋白酶抑制剂对两种溶酶体外蛋白酶(多催化蛋白酶复合体和 m-钙蛋白酶)作用效果的比较。
J Neurochem. 1994 May;62(5):1989-94. doi: 10.1046/j.1471-4159.1994.62051989.x.
5
Evidence for participation of a calpain-like cysteine protease in cell cycle progression through late G1 phase.一种类钙蛋白酶半胱氨酸蛋白酶参与细胞周期通过G1期晚期进程的证据。
Biochem Biophys Res Commun. 1997 Jul 30;236(3):555-8. doi: 10.1006/bbrc.1997.7003.
6
Calpain involvement in calphostin C-induced apoptosis.钙蛋白酶参与钙泊三醇C诱导的细胞凋亡。
Biochem Pharmacol. 1998 Dec 1;56(11):1489-92. doi: 10.1016/s0006-2952(98)00169-5.
7
Characterization of the active site of human multicatalytic proteinase.人多催化蛋白酶活性位点的表征
Biochem J. 1990 Jan 15;265(2):479-84. doi: 10.1042/bj2650479.
8
Detailed analysis of cell cycle kinetics upon proteasome inhibition.
Cytometry. 1997 Jul 1;28(3):243-52.
9
Evidence for the participation of the proteasome and calpain in early phases of muscle cell differentiation.蛋白酶体和钙蛋白酶参与肌肉细胞分化早期阶段的证据。
Int J Biochem Cell Biol. 1998 Jun;30(6):679-94. doi: 10.1016/s1357-2725(98)00023-5.
10
Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition.苄氧羰基-亮氨酰-亮氨酰-酪氨酸重氮甲基酮对WI-38成纤维细胞生长的抑制作用:钙蛋白酶样蛋白酶切割p53是G1期到S期转变所必需的证据。
Oncogene. 1997 Jan 23;14(3):255-63. doi: 10.1038/sj.onc.1200841.

引用本文的文献

1
Role of proteases in the pathophysiology of cardiac disease.蛋白酶在心脏疾病病理生理学中的作用。
Mol Cell Biochem. 2004 Aug;263(1):241-56. doi: 10.1023/B:MCBI.0000041865.63445.40.
2
Effects of phosphatase and proteasome inhibitors on Borealin phosphorylation and degradation.磷酸酶和蛋白酶体抑制剂对纺锤体检查点蛋白 Borealin 磷酸化和降解的影响。
J Biochem. 2012 Apr;151(4):361-9. doi: 10.1093/jb/mvs015. Epub 2012 Feb 29.
3
Mitochondrial turnover and aging of long-lived postmitotic cells: the mitochondrial-lysosomal axis theory of aging.
线粒体周转和长寿命有丝分裂后细胞的衰老:衰老的线粒体-溶酶体轴理论。
Antioxid Redox Signal. 2010 Apr;12(4):503-35. doi: 10.1089/ars.2009.2598.
4
Ubiquitin-proteasome degradation of serum- and glucocorticoid-regulated kinase-1 (SGK-1) is mediated by the chaperone-dependent E3 ligase CHIP.伴侣蛋白依赖性E3连接酶CHIP介导血清和糖皮质激素调节激酶-1(SGK-1)的泛素-蛋白酶体降解。
Biochem J. 2006 Dec 1;400(2):235-44. doi: 10.1042/BJ20060905.
5
O2 enhancement of human trophoblast differentiation and hCYP19 (aromatase) gene expression are mediated by proteasomal degradation of USF1 and USF2.氧气对人滋养层细胞分化和hCYP19(芳香化酶)基因表达的增强作用是由USF1和USF2的蛋白酶体降解介导的。
Mol Cell Biol. 2005 Oct;25(20):8824-33. doi: 10.1128/MCB.25.20.8824-8833.2005.
6
Proteasome inhibitors: their effects on arachidonic acid release from cells in culture and arachidonic acid metabolism in rat liver cells.蛋白酶体抑制剂:它们对培养细胞中花生四烯酸释放及大鼠肝细胞中花生四烯酸代谢的影响。
BMC Pharmacol. 2004 Aug 5;4:15. doi: 10.1186/1471-2210-4-15.
7
Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells.蛋白酶体抑制剂PS-341可下调前列腺特异性抗原(PSA),并诱导雄激素依赖性人前列腺癌LNCaP细胞生长停滞和凋亡。
Cancer Sci. 2004 Mar;95(3):271-5. doi: 10.1111/j.1349-7006.2004.tb02215.x.
8
Distinct classes of proteasome-modulating agents cooperatively augment recombinant adeno-associated virus type 2 and type 5-mediated transduction from the apical surfaces of human airway epithelia.不同类别的蛋白酶体调节剂协同增强重组2型和5型腺相关病毒介导的从人气道上皮细胞顶端表面的转导。
J Virol. 2004 Mar;78(6):2863-74. doi: 10.1128/jvi.78.6.2863-2874.2004.
9
Calpain regulates enterocyte brush border actin assembly and pathogenic Escherichia coli-mediated effacement.钙蛋白酶调节肠上皮细胞刷状缘肌动蛋白组装以及致病性大肠杆菌介导的细胞表面损伤。
J Biol Chem. 2003 Aug 8;278(32):30403-12. doi: 10.1074/jbc.M304616200. Epub 2003 May 22.
10
Ligand binding directly stimulates ubiquitination of the inositol 1, 4,5-trisphosphate receptor.配体结合直接刺激1,4,5-三磷酸肌醇受体的泛素化。
Biochem J. 2000 Jun 15;348 Pt 3(Pt 3):551-6.